BioWorld Science

May 26, 2020

View Archived Issues

Atherosclerosis, AD meet at the myelin

Read More

p53 loss leads to immune evasion

Read More

Karus Therapeutics initiates phase II study of KA-2507 in biliary tract cancer

Read More

Enrollment open in phase II study of MSTT-1041A or UTTR-1147A in COVID-19 pneumonia

Read More

Clinical data for novel non-D2-receptor-binding compound in patients with schizophrenia

Read More

DNA-encoded immunotherapies show efficacy in models of N. gonorrhoeae infection

Read More

First-in-human characterization of RPT-193

Read More

IRAK-2 is a therapeutic target in atopic dermatitis and psoriasis

Read More

AiCuris discovers HBV caspid assembly inhibitors

Read More

New SSAO inhibitors identified at Boehringer Ingelheim

Read More

Esteve patents voltage-dependent calcium channel subunit alpha2/delta-1 ligands

Read More

Merck & Co. identifies new LRRK2 inhibitors

Read More

New TYK2 inhibitors disclosed by Bristol-Myers Squibb

Read More

Germline ApoE variants affect melanoma trajectory

Read More

PEG10 found behind pathogenic mechanisms of mycosis fungoides

Read More

Phase III trial of efgartigimod in generalized myasthenia gravis meets primary endpoint

Read More

Chi-Med and BeiGene to study surufatinib and fruquintinib with tislelizumab for solid tumors

Read More

Synairgen's phase II trial begins dosing SNG-001 in home setting to treat COVID-19

Read More

Novartis begins phase II study of DFV-890 for COVID-19 pneumonia

Read More

Glenmark to begin phase III study of favipiravir with umifenovir in moderate COVID-19

Read More

Tavotek and Genmab partner to develop antibody for autoimmune and inflammatory conditions

Read More

Levels of cytokine LIGHT correlate with disease severity and mortality in COVID-19 ARDS study

Read More